Who should consider starting ctDNA screening?

Brochure:
Icon

Patient Guiding Handbook 11.40 MB 86 downloads

Spot early signals of 10 common and aggressive cancers using next generation of ctDNA...
Download
Find out:

Patients

Adults aged less than 40 years but have high risks

View more

Adults aged
40 years & older

View more

What screening options are available for me and my family?

Screening Availability

Complementary Screening:
Annual ctDNA multi–cancer screening for more cancers that do not have screen program yet. Discuss with your primary care doctor to learn more about the test.
Some organs currently have screening programs available for each type. Talk to your primary care doctor for advice. 
Hereditary cancer risks test by informed choice. (Related genes that recommended by American Cancer Society or National Comprehensive Cancer Network)

Screening programs and ctDNA screening

Recommended programs:(1)

  • Breast cancer:
    Annual mammography for women above 
40 years old.
  • Colorectal cancer:
    Start regular Stool–based test or Colonoscopy at age 45.
  • Lung cancer:
    Annual low–dose CT scan people age 50–80 who smoke or used to smoke.
  • Cervical cancer:
    Cervical cytology, HPV/PAP test every 03 or 05 years for people between the age of 25–65.
  • Prostate cancer:
    Prostate–specific antigen (PSA)–based testing starting at age 50 for men.

Breakthrough SPOT–MAS next–generation ctDNA screening test:

Spot for early cancerous signal of:(2)
Basic Option: Top 05 Common Cancers
Breast
Breast
Lung
Lung
Colorectum
Colorectum
Liver
Liver
Stomach
Stomach
Extended option: 05 Less Common But Aggressive Cancers
Uterus
Uterus
Esophagus
Esophagus
Biliary tract
Biliary tract
Pancreas
Pancreas
Ovary
Ovary
● 7/10 currently have no standard–of–care screening program available.

Screening methods complementary to standard–of–care programs are available as informed choices. Talk to your healthcare provider about the pros and cons of testing to make decision.

  • (1) American Cancer Society
  • (2) The number of cancer types varies based on availability in different countries.

Why SPOT-MAS and what do results mean?

Largest clinical validation in Asia:
SPOT–MAS performance is validated in a research involves 9.024 participants, showing proven accuracy in cancer signal detection (78.1% Sensitivity, 99,8% Specificity) and tumor location prediction (84% Accuracy).(1)
The blood specimen is processed and tested at Gene Solutions Genomics Pte Ltd, a MOH–licensed clinical laboratory in Singapore. Results will be delivered to your doctor.

Gene Solutions’ award winning ctDNA technology to screen for multi–cancer has been featured in:

  • American Society of Clinical Oncology (ASCO) Breakthrough 2023
  • European Society for Medical Oncology (ESMO) Asia 2023
  • +14 peer–reviewed international biomedical journal articles, including eLife Science, Nature publications, etc

What do SPOT–MAS results mean?

Negative:
No ctDNA signal detected

ctDNA was not detected at the 
time SPOT–MAS test is conducted. This test provides a snapshot of the blood at the time of collection and does not predict for future cancer risks. 

Next step

Continue with the SPOT–MAS test annually or other screens as recommended by your doctor. Do not ignore cancer signs or symptoms if they occur, as this could lead to a delayed diagnosis.

Positive:
ctDNA signal detected

ctDNA signal associated with tumor cells was detected in the blood. The result may include 1–2 predictions of the origins of tumor in the body where the cancer may be found.

Next step

As the SPOT–MAS test is a screening test, a confirmatory imaging test is required to confirm if cancer is truly present. Your doctor will advise you on the required following tests.

  • (1) Nguyen, et al. “Analytical and clinical validation of a ctDNA based assay for multi–cancer early detection” (2023). doi:10.1101/2023.12.22.23300420

Patient Support Programs

For patients with a positive test result, partial reimbursement for following up diagnostic tests are available in some countries. Discuss with your doctor or contact us to learn more.

SPOT-MAS Videos

Play Video
Play Video
Play Video

Test Process

01

Request the test

Request the test through your primary care doctor. A prescription and 10ml blood collection are required.

02

Sequencing of cfDNA

Your extracted DNA from the plasma will be sequenced by Next–generation ctDNA technology to analyze methylation profile and multi–feature of DNA.

03

Returning results

Receive your ctDNA signal analysis results after 20 working days from the time sample is received at Gene Solutions Genomics Singapore laboratory.

Adults aged 
less than 40 years 
but have high risks

  1. Heavy smoking
People who have a 20 pack–year history 
of smoking.(1)
  2. Heavy drinking
People who drink 15 cans of beer a week (for men) or 08 cans of beer a week 
(for women).(2)
  3. Hereditary risks
Those who have had tested positive for inherited cancer genes such as BRCA1, BRCA2, TP53.(3)
  4. Liver diseases
People who have Hepatitis B or C.(4)
  5. Familial history People whose family members had been diagnosed with cancer.(5)
(1) Chen et al., 2021. American Journal of Otolaryngology 42, 102915. (2) Connor et al., 2017. Addiction 112, 222–228. (3) Garber et al., 2005. JCO 23, 276–292. (4) Petruzziello et al., 2018. TOVJ 12, 26–32. (5) Brewer et al., 2017. Breast Cancer Res Treat 165, 193–200. 

Adults aged 
less than 40 years 
but have high risks

The likelihood of cancer has increased since 1990. Older persons are at higher risk for cancer.(1)
Globally, breast cancer screening is recommended for women above 40 years old(2). Some countries recommend to screen for colon(3), stomach(4), lung(5), and liver(6) starting from as early as 40 years old.​
(1) Sharma et al., 2024. The Lancet Regional Health – Southeast Asia 21, 100333.  (2) Renet al., 2022. The Breast 64, 85–99.  (3) Azad NS et al., 2020. Prev Med. 2020;133:106003. (4) Mabe et al., 2022. Digestive Endoscopy 34, 412–419.  (5) Nawa et al., 2019. Japanese Journal of Clinical Oncology 49, 130–136. (6) Lee et al., 2014. Cancer Res Treat 46, 223–233. 

SPOT-MAS video